No Material Adverse Effect or Material Adverse Change. Except as otherwise disclosed in any Commission Documents, since September 14, 2022: (i) the Company has not experienced or suffered any Material Adverse Effect, and there exists no current state of facts, condition or event which would have a Material Adverse Effect; (ii) there has not occurred any material adverse change, or any development that would reasonably be expected to result in a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company from that set forth in the Commission Documents.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Amprius Technologies, Inc.)
No Material Adverse Effect or Material Adverse Change. Except as otherwise disclosed in any Commission Documents, since September 14December 31, 20222021: (i) the Company has not experienced or suffered any Material Adverse Effect, and there exists no current state of facts, condition or event which would have a Material Adverse Effect; (ii) there has not occurred any material adverse changeMaterial Adverse Effect, or any current development that would reasonably be expected to result in a prospective material adverse change, Material Adverse Effect and (ii) the Company and its Subsidiaries have conducted their respective businesses in the condition, financial or otherwise, or ordinary course of business consistent with past practice in the earnings, business or operations of the Company from that set forth in the Commission Documentsall material respects.
Appears in 1 contract
No Material Adverse Effect or Material Adverse Change. Except as otherwise disclosed in any Commission Documents, since September 14December 31, 20222023: (i) the Company has not experienced or suffered any Material Adverse Effect, and there exists no current state of facts, condition or event which would have a Material Adverse Effect; and (ii) there has not occurred any material adverse change, or any development that would reasonably be expected to result in a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company from that set forth in the Commission Documents.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (MultiSensor AI Holdings, Inc.)
No Material Adverse Effect or Material Adverse Change. Except as otherwise disclosed in any Commission Documents, since September 14December 31, 2022: (i) the Company has not experienced or suffered any Material Adverse Effect, and there exists no current state of facts, condition or event which would reasonably be expected to have a Material Adverse Effect; (ii) there has not occurred any material adverse change, or any development that would reasonably be expected to result in a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company from that set forth has conducted its business consistent with past practice in the Commission Documentsall material respects.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Monogram Orthopaedics Inc)
No Material Adverse Effect or Material Adverse Change. Except as otherwise disclosed in any Commission Documents, since September 14December 31, 2022: (i) the Company has not experienced or suffered any Material Adverse Effect, and there exists no current state of facts, condition or event which would reasonably be expected to have a Material Adverse Effect; (ii) there has not occurred any material adverse change, or any development that would reasonably be expected to result in a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company from that set forth has conducted its business consistent with past practice in the Commission Documents.all material respects. β
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Monogram Orthopaedics Inc)
No Material Adverse Effect or Material Adverse Change. Except as otherwise disclosed in any Commission Documents, since September 14January 19, 2022: (i) the Company has not experienced or suffered any Material Adverse Effect, and there exists no current state of facts, condition or event which would reasonably be expected to have a Material Adverse Effect; and (ii) there has not occurred any material adverse change, or any development that would reasonably be expected to result in a prospective material adverse change, in the condition, financial or otherwise, or in the earnings, business or operations of the Company from that set forth and Subsidiaries have conducted their respective business consistent with past practice in the Commission Documentsall material respects.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Core Scientific, Inc./Tx)